ACADIA Cash from 2010 to 2025

ACAD Stock  USD 17.18  0.11  0.64%   
ACADIA Pharmaceuticals' Cash is increasing over the years with slightly volatile fluctuation. Overall, Cash is expected to go to about 335.6 M this year. Cash is the total amount of money in the form of currency that ACADIA Pharmaceuticals has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2002-12-31
Previous Quarter
155.1 M
Current Value
319.6 M
Quarterly Volatility
99.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ACADIA Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ACADIA Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 8 M, Selling General Administrative of 512.8 M or Total Revenue of 1 B, as well as many indicators such as Price To Sales Ratio of 3.02, Dividend Yield of 0.0 or PTB Ratio of 4.46. ACADIA financial statements analysis is a perfect complement when working with ACADIA Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

Latest ACADIA Pharmaceuticals' Cash Growth Pattern

Below is the plot of the Cash of ACADIA Pharmaceuticals over the last few years. Cash refers to the most liquid asset of ACADIA Pharmaceuticals, which is listed under current asset account on ACADIA Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from ACADIA Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different ACADIA Pharmaceuticals account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. ACADIA Pharmaceuticals' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ACADIA Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

ACADIA Cash Regression Statistics

Arithmetic Mean139,658,753
Geometric Mean82,099,415
Coefficient Of Variation79.09
Mean Deviation86,620,772
Median134,758,000
Standard Deviation110,461,442
Sample Variance12201.7T
Range331.1M
R-Value0.84
Mean Square Error3838T
R-Squared0.71
Significance0.000046
Slope19,500,660
Total Sum of Squares183026T

ACADIA Cash History

2025335.6 M
2024319.6 M
2023188.7 M
2022114.8 M
2021147.4 M
2020326 M
2019189.7 M

Other Fundumenentals of ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Cash component correlations

About ACADIA Pharmaceuticals Financial Statements

ACADIA Pharmaceuticals stakeholders use historical fundamental indicators, such as ACADIA Pharmaceuticals' Cash, to determine how well the company is positioned to perform in the future. Although ACADIA Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in ACADIA Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on ACADIA Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ACADIA Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash319.6 M335.6 M
Cash And Short Term Investments756 M793.8 M
Other Non Cash Items-141.4 M-134.4 M
End Period Cash Flow328.4 M344.8 M
Change In Cash133.9 M140.6 M
Free Cash Flow157.2 M165.1 M
Begin Period Cash Flow194.4 M204.1 M
Total Cashflows From Investing Activities65.9 M69.2 M
Other Cashflows From Financing Activities36.8 M71.1 M
Total Cash From Operating Activities157.7 M165.6 M
Total Cash From Financing Activities6.8 M6.5 M
Cash And Cash Equivalents Changes-160.7 M-152.7 M
Cash Flows Other Operating2.4 M2.5 M
Other Cashflows From Investing Activities146.5 M153.8 M
Free Cash Flow Yield 0.05  0.05 
Operating Cash Flow Per Share 0.95  1.00 
Free Cash Flow Per Share 0.95  1.00 
Cash Per Share 4.56  4.13 
EV To Operating Cash Flow 17.58  18.46 
EV To Free Cash Flow 17.64  18.52 
Price To Operating Cash Flows Ratio 19.28  20.24 
Price To Free Cash Flows Ratio 19.34  20.31 
Cash Ratio 0.81  0.77 
Cash Conversion Cycle 63.30  60.14 
Operating Cash Flow Sales Ratio 0.16  0.17 
Free Cash Flow Operating Cash Flow Ratio 1.00  1.00 
Cash Flow Coverage Ratios 3.03  3.19 
Price Cash Flow Ratio 19.28  20.24 
Cash Flow To Debt Ratio 3.03  3.19 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.133
Earnings Share
1.36
Revenue Per Share
5.78
Quarterly Revenue Growth
0.124
Return On Assets
0.0544
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.